News

UroToday2d
ASCO 2025: Ipilimumab/nivolumab Versus Standard of Care in Non-Clear Cell Renal Cancer: Results of the SUNNIFORECAST Trial and Potential Role of the CPS Score and Tumor Nephrectomy
ASCO 2025, Renal Cancer, kidney cancer, Non-clear cell renal cell carcinoma (non-ccRCC), Ipilimumab, nivolumab, SUNNIFORECAST Trial, Tumor Nephrectomy, tyrosine kinase inhibitors (TKIs), immune ...
UroToday2d
ASCO 2025: Navigating the Crossroads: Evolving Paradigms in Perioperative Management of Muscle-Invasive Bladder Cancer
ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT), SWOG 8710 trial, PURE-01 trial, NIAGARA trial, ABACUS trial, CheckMate 274 trial, ImVigor 010, atezolizumab, ...
UroToday3d
ASCO 2025: Clonal Hematopoiesis in Participants with mCRPC Receiving 177Lu-PSMA-617 or Cabazitaxel: An Exploratory Post-Hoc Analysis of a Randomized Phase II Trial (TheraP ...
ASCO 2025 post-hoc analysis of TheraP, clonal hematopoiesis, metastatic castration-resistant prostate cancer (mCRPC), 177Lu-PSMA-617, cabazitaxel, PSMA-targeted radioligand.
UroToday3d
ASCO 2025: CA209-8TY Trial, a Randomized Phase 2 Trial of Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in mCRPC
ASCO 2025 CA209-8TY trial, phase 2 trial of nivolumab and ipilimumab, stereotactic body radiation therapy, metastatic castration-resistant prostate cancer (mCRPC), androgen receptor pathway inhibitors ...
UroToday3d
ASCO 2025: Association of Circulating Immune and Metabolic Markers with Clinical Outcomes in the ENZAMET Trial (ANZUP 1304)
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...
UroToday3d
ASCO 2025: Assessing Treatment Outcomes of Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
ASCO 2025, urothelial carcinoma (UC), Metastatic Bladder Cancer, Enfortumab Vedotin (EV), Dose Reduction in Metastatic Bladder Cancer, Nectin-4.
UroToday3d
ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...
UroToday4d
PSMA and Beyond 2025: Landscape of Approved PSMA Imaging Agents: Does It Matter?
PSMA and Beyond 2025 approved PSMA imaging agents, evolution of PSMA imaging agents, UCSF/UCLA 68Ga-PSMA-11 trial, OSPREY 18F-DCFPyL trial, LIGHTHOUSE 18F-rhPSMA 7.3 trial.
UroToday5d
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
ASCO 2025 Artera's ASCO 2025 first validated MMAI algorithm—used in the ArteraAI Prostate Test shows its AI test may identify which high-risk prostate cancer patients benefit from ARPI, sparing many ...
UroToday5d
Procedure for Changing a Suprapubic Catheter (SPC or SPT)
initial insertion of a suprapubic catheter (SPC), suprapubic cystostomy, insertion for bladder outlet obstruction, indwelling urethral catheter (IUC), urology nursing practice, Diane Newman.
UroToday6d
ASCO 2025: Phase 3, Randomized, Placebo-Controlled Clinical Trial of CAN-2409 + Prodrug in Combination with Standard of Care External Beam Radiation for Newly Diagnosed ...
ASCO 2025, Prostate Cancer, androgen deprivation therapy (ADT), HSV-tk gene, Prodrug, intraprostatic injections of CAN-2409, CAN-2409, CAN-2409 plus Prodrug, External Beam Radiation for Newly ...
UroToday6d
ASCO 2025: Trials-in-Progress – Sasanlimab as Bladder-Sparing Maintenance Treatment After Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer (MIBC): The ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.